Novo Nordisk to Invest $1.09 Billion in Brazil to Expand GLP-1 Drug Production Capacity

Apr 10, 2025 09:12 CST Updated 09:12

Novo Nordisk

Insulin Developer and Manufacturer

Note:This article does not constitute any investment opinions or suggestions; please refer to official/company announcements for accuracy.This article is only for the introduction of medical and health-related drugs, not a recommendation of treatment options (if involved), and does not represent the platform's position.Any article reprinted needs to be authorized.

Recently,Novo Nordisk announced plans to invest up to USD 1.09 billion (approximately DKK 6 billion) in expanding its existing manufacturing site in Montes Claros, Brazil. The newly expanded production facility will primarily focus on the company’s core products: the GLP-1 diabetes medication Ozempic and the weight management drug Wegovy.

According to the company's plan, the production base is expected toCompleted construction before 2028, and will createMore than 500 high-tech positionsNovo Nordisk's investment plan in Brazil this time is one of the largest pharmaceutical investments in history. This huge amount of funds will be used to introduce advanced aseptic production processes, expand warehouse capacity, and build new high-quality control laboratories. Such a large-scale expansion marks Novo Nordisk's emphasis on the Brazilian market and its further layout in the Latin American market.

This investment comes as Brazilian pharmaceutical companies, such as Hypera, are preparing to enter the growing GLP-1 market. Hypera recently announced plans to launch its generic version of Ozempic once the drug’s patent expires in Brazil. Novo Nordisk stated it is not concerned about the patent expiration, noting that this is a common occurrence in the industry. The global trade war initiated by Trump will not impact the plant, as the United States is not a destination for Brazilian-made products, and Novo Nordisk is separately expanding its production capacity in the U.S.

References:

www.endpts.com

Copyright statement: This article is reproduced from the Biopharmaceutical Era，Media or individuals who do not wish to be reprinted can contact us, and we will delete it immediately.

Conference Recommendation | Click to View Details

Rooted in Shanghai and radiating globally, PharmaCircle, as a strategic platform for the biopharmaceutical industry, is on a mission to "enable the boundless flow of intelligence and networks." It has built an empowering system that covers the entire pharmaceutical industrial chain, including R&D, production, distribution, and commercialization. Through four core engines—intelligent cloud services, precise resource connections, industry think tanks, and ecosystem communities—it is creating the infrastructure for the flow of pharmaceutical value in China.

Under the dual waves of globalization and digitalization, PharmaCircle is redefining the circulation paradigm of pharmaceutical resources — it is not only a hub for information and networking but also a catalyst for industrial transformation. With China as the origin, we are weaving a global network of pharmaceutical intelligence, making every precise connection a catalyst for leapfrog business growth.

Like

Share

Recommended Point